UNSPSC 51434106: Chlorisondamine chloride

This classification denotes a nicotinic antagonist with the molecular formula C14H20Cl4N2.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B58W7756G, chemically known as 4,5,6,7-tetrachloro-2-(2-dimethylaminoethyl)-isoindoline dimethochloride but more generally known as chlorisondamine chloride, which bears US NIH Compound Identifier 6243. European Medicines Agency schedules Chlorisondamine chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06182MIG.

UNSPSC 51434106 Chlorisondamine chloride is a Commodity code tracking a specific pharmaceutical active ingredient used in emergency medical treatments. State and local governments procure this substance primarily as part of Advanced Life Support medication supply contracts for fire rescue and emergency medical services operations. The code reflects sourcing of individual pharmaceutical line items or bulk active pharmaceutical ingredients that support emergency response capabilities, particularly through municipal fire departments and regional health systems. Issuing bodies include city procurement offices managing emergency services contracts and state health agencies coordinating pharmacy benefit programs and direct-to-manufacturer procurement initiatives. The work involves sourcing, warehousing, and delivery of pharmaceutical products meeting FDA compliance, expiration-date requirements, and OSHA Hazard Communication Standards, often with small-business set-asides or cooperative purchasing frameworks.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (including epinephrine, adenosine, diltiazem, and labetalol) to supply Tampa Fire Rescue, with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured state pharmacy benefit plans, signaling future formal procurement activity. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating states including Oregon, with proposals due March 26, 2026, requiring distribution through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, and contract effectiveness set for July 1, 2026.